{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:27:20Z","timestamp":1793662040471,"version":"4.5.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UG1 EY28096"],"award-info":[{"award-number":["UG1 EY28096"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UG1 EY028091"],"award-info":[{"award-number":["UG1 EY028091"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UG1 EY028087"],"award-info":[{"award-number":["UG1 EY028087"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ophtha.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:28:00Z","timestamp":1760164080000},"page":"310-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-1361","authenticated-orcid":false,"given":"Douglas A.","family":"Jabs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Sugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyce E.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1554-3211","authenticated-orcid":false,"given":"Michael","family":"Altaweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheriza","family":"Baksh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-685X","authenticated-orcid":false,"given":"Lyndell","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet T.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ophtha.2025.10.004_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","article-title":"Approach to the diagnosis of the uveitides","volume":"156","author":"Jabs","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.004_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.10.004_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/epirev\/mxac001","article-title":"The conundrum of clinical trials for the uveitides: appropriate outcome measures for one treatment used in several diseases","volume":"44","author":"Jabs","year":"2022","journal-title":"Epidemiol Rev"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.004_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/09273940490883671","article-title":"Treatment of ocular inflammation","volume":"12","author":"Jabs","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ophtha.2025.10.004_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.004_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2005.01.035","article-title":"Birdshot retinochoroidopathy: ocular complications and visual impairment","volume":"140","author":"Thorne","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.004_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2007.08.039","article-title":"Loss of visual field among patients with birdshot chorioretinopathy","volume":"145","author":"Thorne","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2025.10.004_bib8","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.ophtha.2006.05.067","article-title":"Multifocal choroiditis with panuveitis: incidence of ocular complications and of loss of visual acuity","volume":"113","author":"Thorne","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.004_bib9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ajo.2005.04.052","article-title":"Vogt-Koyanagi-Harada disease: clinical outcomes","volume":"140","author":"Bykhovskaya","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.004_bib10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","article-title":"Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss","volume":"152","author":"Taylor","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.004_bib11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ajo.2014.08.039","article-title":"Success with single agent immunosuppression for multifocal choroidopathies","volume":"158","author":"Goldberg","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.004_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","article-title":"Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss","volume":"143","author":"Thorne","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.004_bib13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Systemic Immunosuppressive Therapy for Eye Disease Cohort Study Group. Ocular inflammation in Beh\u00e7et disease: incidence of ocular complications and of loss of visual acuity","volume":"146","author":"Kacmaz","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2025.10.004_bib14","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","year":"2011","journal-title":"Ophthalmology"},{"issue":"19","key":"10.1016\/j.ophtha.2025.10.004_bib15","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","year":"2017","journal-title":"J Amer Med Assoc"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.004_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ophtha.2025.10.004_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ophtha.2025.10.004_bib18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.004_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.004_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.004_bib21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs. tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.004_bib22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.004_bib23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/IAE.0000000000003836","article-title":"Tacrolimus for immunosuppression in patients with non-infectious intermediate, posterior, or panuveitides","volume":"43","author":"Jabs","year":"2023","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ophtha.2025.10.004_bib24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active non-infectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"10.1016\/j.ophtha.2025.10.004_bib25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for the prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicenter, double-masked, randomized, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.004_bib26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","article-title":"Long-term safety and efficacy of adalimumab in patients with non-infectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"128","author":"Suhler","year":"2021","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2025.10.004_bib27","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for non-infectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.004_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2019.07.008","article-title":"Comparison between methotrexate and mycophenolate for the control of non-infectious ocular inflammatory disease","volume":"208","author":"Gangaputra","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2025.10.004_bib29","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate vs. methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ophtha.2025.10.004_bib30","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jamaophthalmol.2019.3964","article-title":"Antimetabolite therapy for uveitis, methotrexate or mycophenolate?","volume":"137","author":"Jabs","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2025.10.004_bib31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamaophthalmol.2020.1864","article-title":"Stratification clarification for methods for randomized clinical trials\u2014reply","volume":"138","author":"Jabs","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.004_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.004_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0161-6420(96)30742-2","article-title":"Standardizing the measurement of visual acuity for clinical research studies: guidelines from the Eye Care Technology Forum","volume":"103","author":"Ferris","year":"1996","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.004_bib34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.004_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.004_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00647843","article-title":"Criterion validity and reliability of the SF-36 in a population sample","volume":"3","author":"Jenkinson","year":"1994","journal-title":"Qual Life Res"},{"issue":"6846","key":"10.1016\/j.ophtha.2025.10.004_bib37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ophtha.2025.10.004_bib38","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2025.10.004_bib39","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.ophtha.2020.07.038","article-title":"Responsiveness of vision-specific and general quality of life metrics to ocular and systemic events in patients with uveitis","volume":"127","author":"Sugar","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.004_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.004_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archophthalmol.2009.368","article-title":"Fundus autofluorescence imaging of the white dot syndromes","volume":"128","author":"Yeh","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2025.10.004_bib42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/IAE.0b013e318286cc77","article-title":"Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging","volume":"33","author":"Spaide","year":"2013","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.004_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/09273948.2013.855797","article-title":"Fundus autofluorescence imaging in multifocal choroiditis: beyond the spots","volume":"22","author":"Kramer","year":"2013","journal-title":"Ocular Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2025.10.004_bib44","series-title":"Statistical Analysis with Missing Data","author":"Little","year":"2002"},{"key":"10.1016\/j.ophtha.2025.10.004_bib45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","article-title":"Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK","volume":"5","author":"Gale","year":"2018","journal-title":"Rheumatoid Ther"},{"issue":"11","key":"10.1016\/j.ophtha.2025.10.004_bib46","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1016\/S2665-9913(24)00194-2","article-title":"Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behcet\u2019s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial","volume":"6","author":"Zhong","year":"2024","journal-title":"Lancet Rhematol"},{"key":"10.1016\/j.ophtha.2025.10.004_bib47","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/09273948.2021.1936565","article-title":"Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case series","volume":"30","author":"McKay","year":"2022","journal-title":"Ocular Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2025.10.004_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29313","article-title":"Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis","volume":"10","author":"Bromeo","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.004_bib49","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","article-title":"Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis","volume":"104","author":"Baumgarter","year":"2019","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ophtha.2025.10.004_bib50","first-page":"1043","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2025.10.004_bib51","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","article-title":"Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy","volume":"240","author":"Eurelings","year":"2022","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:42:22Z","timestamp":1778013742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025006396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0161642025006396"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.004","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}